Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW Preparatory Council Boots Up for Japan-Version of CDC
The Ministry of Health, Labor and Welfare (MHLW) on October 12 launched a preparatory council towards the establishment of a so-called Japanese version of the US Centers for Disease Control and Prevention (CDC), which is expected to be set up…
To read the full story
Related Article
- NCGM President to Take Helm of Japan CDC after April Merger
August 29, 2024
- MHLW Holds 1st Meeting to Consider Structure of Japan CDC
January 26, 2024
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- Japan Diet Enacts Bill to Create “Japan CDC”
June 1, 2023
- Japan Cabinet Approves Bill to Create “Japan CDC”
March 8, 2023
- MHLW Planning to Submit 6 Bills in Ordinary Diet Session, “Japan CDC” Plan Included
January 13, 2023
REGULATORY
- LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
- MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
- MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
June 19, 2026
- LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
June 19, 2026
- LDP Patch League Urges Drug Price Support as Costs Continue to Climb
June 19, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…